Mark P. Stevenson
Known title: Executive Vice President & COOCIK: 0001387890
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Thermo Fisher Outperforms on Life Sciences Recovery. Thermo Fisher Scientific reported strong results driven by a recovery in the life sciences sector. Growth in academic and government spending is supporting demand for the company's products. Analysts note that increasing omics demand could further influence the stock's outlook.
Transaction History
| IR | ▲ Buy | Option Exercise | 2,309 | — | 2/26/2026 | View on chart |
| IR | ▲ Buy | Option Exercise | 2,129 | — | 2/27/2025 | View on chart |
| IR | ▲ Buy | Option Exercise | 3,022 | — | 2/23/2024 | View on chart |
| IR | ▲ Buy | Option Exercise | 1,757 | — | 8/5/2023 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,880 | $1.0M | 2/25/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,200 | $634K | 2/23/2022 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,035 | $547K | 2/23/2022 | View on chart |
| TMO | ▲ Buy | Grant | 7,000 | $0 | 2/23/2022 | View on chart |
| TMO | ▲ Buy | Option Exercise | 12,375 | $2.0M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,738 | $1.1M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,759 | $1.7M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,307 | $832K | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 4,731 | $3.0M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 3,354 | $2.1M | 12/1/2021 | View on chart |
| TMO | ▲ Buy | Option Exercise | 14,550 | $2.8M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,408 | $882K | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,364 | $856K | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,350 | $1.5M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,393 | $1.5M | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,204 | $764K | 12/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 4,317 | $2.7M | 12/1/2021 | View on chart |
| TMO | ▲ Buy | Option Exercise | 12,375 | $2.0M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,500 | $953K | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 5,004 | $3.2M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 4,008 | $2.6M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 3,848 | $2.5M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 5,741 | $3.7M | 11/2/2021 | View on chart |
| TMO | ▲ Buy | Option Exercise | 14,550 | $2.8M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 3,682 | $2.3M | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 609 | $391K | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 500 | $317K | 11/2/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,033 | $1.3M | 11/2/2021 | View on chart |
| TMO | ▲ Buy | Option Exercise | 14,550 | $2.8M | 11/1/2021 | View on chart |
| TMO | ▲ Buy | Option Exercise | 12,375 | $2.0M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,367 | $1.5M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 5,209 | $3.3M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 900 | $572K | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 800 | $509K | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 6,169 | $3.9M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 2,000 | $1.3M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 1,570 | $987K | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 4,141 | $2.6M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Open Market | 3,769 | $2.4M | 11/1/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,158 | $635K | 8/27/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 1,038 | $574K | 8/26/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 635 | $348K | 8/25/2021 | View on chart |
| TMO | ▼ Sell | Tax Withholding | 267 | $148K | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ingersoll Rand News: Growth, Earnings Outlook, and Risk Review
Recent articles highlight Ingersoll Rand’s solid growth but note that analysts have not upgraded the stock. Another piece outlines expectations for the company’s Q3 2026 earnings, while a third review praises its durable economics. A recent risk assessment lists the stock as one of two considered risky among industrials, adding a cautionary note to its profile.
Ingersoll Rand News: Growth, Earnings Outlook, and Risk Review. Recent articles highlight Ingersoll Rand’s solid growth but note that analysts have not upgraded the stock. Another piece outlines expectations for the company’s Q3 2026 earnings, while a third review praises its durable economics. A recent risk assessment lists the stock as one of two considered risky among industrials, adding a cautionary note to its profile.